New cocktail aims to knock out tough prostate cancer
NCT ID NCT02772588
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving three hormone-blocking drugs along with high-dose, precisely targeted radiation could stop very high-risk prostate cancer from coming back. Sixty-four men with aggressive prostate cancer received the treatment. The main goal was to see how many men had a rise in their PSA levels, which would signal the cancer had returned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide, abiraterone, leuprolide, and high-dose precision radiation
What this could lead to
If successful, this combination could offer a more effective way to prevent prostate cancer from coming back in very high-risk patients.
What could go wrong
This is a small, single-arm phase 2 study with no comparison group, so results may not apply broadly. Hormone therapy can cause side effects like hot flashes and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Hopkins Medical Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Rockville
Rockville Centre, New York, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
Weill Cornell Medical Center
New York, New York, 10065, United States